Stable Evans Blue Derived Exendin-4 Peptide for Type 2 Diabetes Treatment

被引：26

作者：

Liu, Yi ^{[1
,2
]}

Wang, Guohao ^{[3
]}

Zhang, Huimin ^{[2
]}

Ma, Ying ^{[2
]}

Lang, Lixin ^{[2
]}

Jacobson, Orit ^{[2
]}

Kiesewetter, Dale O. ^{[2
]}

Zhu, Lei ^{[3
]}

Gao, Shi ^{[1
]}

Ma, Qingjie ^{[1
]}

Chen, Xiaoyuan ^{[2
]}

机构：

[1] Jilin Univ, China Japan Union Hosp, Changchun 130033, Jilin, Peoples R China

[2] NIBIB, LOMIN, NIH, Bethesda, MD 20892 USA

[3] Xiamen Univ, Sch Publ Hlth, Ctr Mol Imaging & Translat Med, State Key Lab Mol Vaccinol & Mol Diagnost, Xiamen 361102, Peoples R China

来源：

BIOCONJUGATE CHEMISTRY | 2016年 / 27卷 / 01期

基金：

美国国家科学基金会; 美国国家卫生研究院;

关键词：

ALBUMIN-BINDING; RECEPTOR; INSULIN; ANALOG; PHARMACOKINETICS; MALEIMIDES; MECHANISM; STRATEGY; AGONIST;

D O I：

10.1021/acs.bioconjchem.5b00625

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

In the treatment of type 2 diabetes mellitus, it is very important to develop therapeutics with prolonged circulation half-life. Exendin-4 is a glucagon like peptide-1 receptor (GLP-1R) agonist that has been modified in different ways for imaging insulinoma and for treating type-2 diabetes. In this work, we synthesized a maleimide derivative of truncated Evans blue dye (MEB-C3-Mal) to conjugate with (Cys(40))exendin-4 to obtain a highly stable MEB-C3-(Cys(40))exendin-4 (denoted as Abextide II). Through in situ binding with endogenous albumin, Abextide II lowers blood glucose level and prolongs the hypoglycemic effect in a type 2 diabetes mouse model more than the FDA approved Albiglutide.

引用

下载

页码：54 / 58

页数：5

共 50 条

[1] The study on the exendin-4 mimetics for the treatment of type 2 diabetes
Xiangwei, Song
Xinhui, Xiong
Jianli, Niu
Liping, Wang
Wei, Li
JOURNAL OF PEPTIDE SCIENCE, 2008, 14 (08) : 115 - 115
[2] The screening of the exendin-4 mimetics for the treatment of type 2 diabetes
Li, W.
Wang, L.
Xu, C.
BIOPOLYMERS, 2007, 88 (04) : 558 - 558
[3] Exendin-4–encapsulated dissolving microneedle arrays for efficient treatment of type 2 diabetes
Shayan Fakhraei Lahiji
Yoojung Jang
Inyoung Huh
Huisuk Yang
Mingyu Jang
Hyungil Jung
Scientific Reports, 8
[4] Effects of exendin-4 on islets from type 2 diabetes patients
Lupi, R.
Mancarella, R.
Del Guerra, S.
Bugliani, M.
Del Prato, S.
Boggi, U.
Mosca, F.
Filipponi, F.
Marchetti, P.
DIABETES OBESITY & METABOLISM, 2008, 10 (06): : 515 - U8
[5] Exendin-4 normalizes glycemic excursions in C-peptide-negative type 1 diabetes
Behme, M
Dupre, J
McDonald, T
DIABETES, 2003, 52 : A110 - A110
[6] Combined treatment with lisofylline and exendin-4 reverses autoimmune diabetes
Yang, Zandong
Chen, Meng
Carter, Jeffrey D.
Nunemaker, Craig S.
Garmey, James C.
Kimble, Sarah D.
Nadler, Jerry L.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 344 (03) : 1017 - 1022
[7] Exendin-4 - A potential therapeutic for type 2 diabetes-linked cervical cancer?
Mishra, Nivida
Mishra, Suresh
EBIOMEDICINE, 2021, 65
[8] Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes
Dupré, J
Behme, MT
McDonald, TJ
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (07): : 3469 - 3473
[9] Design of a Dual Agonist of Exendin-4 and FGF21 as a Potential Treatment for Type 2 Diabetes Mellitus and Obesity
Zhang, Changzhen
Gao, Guosheng
Li, Yafeng
Ying, Jingjing
Li, Jianhui
Hu, Supei
IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2023, 22 (01):
[10] Effects of exenatide (exendin-4) on glycemic control and weight in overweight patients with type 2 diabetes
Blonde, L
Trautmann, M
Holcombe, J
Han, J
Kim, D
OBESITY RESEARCH, 2004, 12 : A39 - A39

← 1 2 3 4 5 →